All In Biotech

Drug Trial Radar · NCT03505853

A Study to Investigate the Interaction Between Givosiran and a 5-probe Drug Cocktail in Patients With Acute Intermittent Porphyria (AIP)

A Drug-Drug Interaction Study to Investigate the Effect of Givosiran on the Pharmacokinetics (PK) of Midazolam, Caffeine, Losartan, Omeprazole, and Dextromethorphan in Patients With Acute Intermittent Porphyria (AIP) Who Are Asymptomatic High Excreters (ASHE)

Last checked: Nov 20, 2026Latest source record: Mar 12, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

10

Actual

Start

Apr 26, 2018

Primary completion

Nov 16, 2018

Study completion Jan 10, 2019

Sponsor

Lead sponsor
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
Sponsor type
Industry
First posted
Apr 23, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the effect of givosiran on the pharmacokinetics of the 5-probe cocktail of midazolam, caffeine, losartan, omeprazole, and dextromethorphan, and their metabolites, in asymptomatic patients with Acute Intermittent Porphyria.

Conditions

  • Acute Intermittent Porphyria (AIP)
  • Acute Hepatic Porphyria (AHP)
  • Porphyria, Acute Intermittent
  • Acute Porphyria

Interventions

  • GivosiranDrug

    single dose of givosiran by subcutaneous (sc) injection

  • 5-probe cocktailDrug

    includes midazolam, caffeine, losartan, omeprazole, and dextromethorphan

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Profile of Pharmacokinetics (PK) of Cytochrome P450 (CYP) probe cocktailTime frame: Days 1 and 36
  2. Profile of Pharmacokinetics (PK) of Cytochrome P450 (CYP) probe cocktailTime frame: Days 1 and 36

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Clinical Trial Site

    Stockholm, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.